Standardisation of cardiac troponin i measurement: Past and present

Pathology

Volumn 42, Issue 5, 2010, Pages 402-408

  Tate, Jillian R ^a   Bunk, David M ^b   Christenson, Robert H ^c   Katrukha, Alexei ^d   Noble, James E ^e   Porter, Robert A ^e   Schimmel, Heinz ^f   Wang, Lili ^g   Panteghini, Mauro ^h  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b Physical and Chemical Properties Division   (United States)

^c NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e HyTest Ltd   (Finland)

^f NATIONAL PHYSICAL LABORATORY   (United Kingdom)

^g JOINT RESEARCH CENTRE   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

Author keywords

Cardiac troponin I; Measurement traceability; Reference material; Reference measurement procedure; Standardisation

Indexed keywords

TROPONIN I;

BLOOD; CLINICAL CHEMISTRY; HUMAN; IMMUNOASSAY; MYOCARDIAL INFARCTION; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARD; STANDARDS;

CLINICAL CHEMISTRY TESTS; HUMANS; IMMUNOASSAY; MYOCARDIAL INFARCTION; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TROPONIN I;

EID: 77954774602     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.3109/00313025.2010.495246     Document Type: Article

References (45)

1. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996; 335: 1342-1349
2. James S, Armstrong P, Califf R, et al. Troponin-T levels and risk of 30- day outcomes in patients with the acute coronary syndrome: Prospective verification in the GUSTO-IV trial. Am J Med 2003; 115: 178-184
3. Kontos MC, Shah R, Fritz LM, et al. Implication of different cardiac troponin I levels for clinical outcomes and prognosis of acute chest pain patients. J Am Coll Cardiol 2004; 43: 958-965
4. Eggers KI, Jaffe AS, Lind L, et al. Value of cardiac troponin I cutoff concentrations below the 99th percentile for clinical decision-making. Clin Chem 2009; 55: 85-92.
5. Schulz O, Kirpal K, Stein J, et al. Importance of low concentrations of cardiac troponins. Clin Chem 2006; 52: 1614-1615
6. Wilson SR, Sabatine MS, Braunwald E, et al. Detection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: Observations from the PROTECT-TIMI 30 Trial. Am Heart J 2009; 158: 386-391
7. Sabatine MS, Morrow DA, de Lemos JA, et al. Detection of acute changes in circulating troponin in the setting of transient stress testinduced myocardial ischaemia using an ultrasensitive assay: Results from TIMI 35. Eur Heart J 2009; 30: 162-169
8. Mingels A, Jacobs L, Michielsen E, et al. Reference population and marathon runner sera assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and I assays. Clin Chem 2009; 55: 101-108
9. Thygesen K, Alpert JS, White HD on behalf of the Joint SC/ACCF/ AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Circulation 2007; 116: 2634-2653
10. Apple FS, Jesse RL, Newby LK, et al. for the NACB committee members and the IFCC Committee on Standardization of Markers of Cardiac Damage (C-SMCD). National Academy of Clinical Biochemistry and IFCC Committee on Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes. Clin Chem 2007; 53: 547-551
11. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Committee on the Standardization of Markers of Cardiac Damage (C-SMCD). Troponin assay analytical characteristics. Available at: www.ifcc.org/index.asp?cat=Scientific-Activities&scat=SD- Committees&suba=Standardisation-of-Markers-of-Cardiac- Damage-(C-SMCD) &zip=1&dove=1&numero=53 (accessed 4 January 2010).
12. Panteghini M, Pagani F, Yeo KT, et al. Evaluation of imprecision for cardiac troponin assays at low range concentrations. Clin Chem 2004; 50: 327-332
13. NHS Purchasing and Supply Agency. Report 05085: Nine troponin assays. London: Centre for Evidence-based Purchasing, December 2005. Available at: Http://www.pasa.nhs.uk/PASAWeb/NHSprocurement/ CEP/CEPproducts/ DES+catalogue++Laboratory+medicine.htm# Labmedicine (accessed 27 November 2009).
14. Tate JR, Ferguson W, Bais R, et al. The determination of the 99th centile level for troponin assays in an Australian reference population. Ann Clin Biochem 2008; 45: 275-288
15. Venge P, Lagerqvist B, Diderholm E, et al. Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC II substudy). Am J Cardiol 2002; 89: 1035-1041
16. James S, Flodin M, Johnston N, et al. The antibody configurations of cardiac troponin I assays may determine their clinical performance. Clin Chem 2006; 52: 832-837
17. Panteghini M. A critical appraisal of experimental factors influencing the definition of the 99th percentile limit of cardiac troponins. Clin Chem Lab Med 2009; 47: 1179-1182
18. Apple FS, Maturen AJ, Mullins RE, et al. Multicenter clinical and analytical evaluation of the AxSYM troponin-I immunoassay to assist in the diagnosis of myocardial infarction. Clin Chem 1999; 45: 206-212
19. Christenson RH, Duh SH, Apple FS, et al. Towards standardization of cardiac troponin I measurements. Part II: Assessing commutability of candidate reference materials and harmonization of cardiac troponin I assays. Clin Chem 2006; 52: 1685-1692
20. Katrukha A, Bereznikova A, Pettersson K. New approach to standardization of human cardiac troponin I (cTnI). Scand J Clin Lab Invest 1999; 59 (Suppl 230): 124-127
21. Tate JR. Troponin revisited 2008: Assay performance. Clin Chem Lab Med 2008; 46: 1489-1500
22. Katrukha AG, Bereznikova AV, Filatov VL, et al. Degradation of cardiac troponin I: Implication for reliable immunodetection. Clin Chem 1998; 44: 2433-2440
23. Labugger R, Organ L, Collier C, et al. Extensive troponin I and T modification detected in serum from patients with acute myocardial infarction. Circulation 2000; 102: 1221-1226
24. McDonough JL, Van Eyk JE. Developing the next generation of cardiac markers: Disease induced modifications of troponin I. Prog Cardiovasc Dis 2004; 47: 207-216
25. Katrukha AG, Bereznikova AV, Esakova TV, et al. Troponin I is released in bloodstream of patients with acute myocardial infarction not in free form but as complex. Clin Chem 1997; 43: 1379-1385
26. Lippi G, Targher G, Franchini M, et al. Genetic and biochemical heterogeneity of cardiac troponins: Clinical and laboratory implications. Clin Chem Lab Med 2009; 47: 1183-1194
27. Wu AHB, Feng YJ, Moore R, et al. Characterization of cardiac troponin subunit release into serum after acute myocardial infarction and comparison of assays for troponin T and I. Clin Chem 1998; 44: 1198-1208
28. Panteghini M. Current concepts in standardization of cardiac marker immunoassays. Clin Chem Lab Med 2004; 42: 3-8.
29. Panteghini M. Selection of antibodies and epitopes for cardiac troponin immunoassays: Should we revise our evidence-based beliefs? Clin Chem 2005; 51: 803-804
30. Panteghini M, Gerhardt W, Apple FS, et al. Quality specifications for cardiac troponin assays. International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Clin Chem Lab Med 2001; 39: 174-178
31. Eriksson S, Halenius H, Pulkki K, et al. Negative interference in cardiac troponin I immunoassays by circulating troponin autoantibodies. Clin Chem 2005; 51: 839-847 (Pubitemid 40577920)
32. Adamczyk M, Brashear RJ, Mattingly PG. Circulating cardiac troponin-I autoantibodies in human plasma and serum. Ann N Y Acad Sci 2009; 1173: 67-74.
33. Panteghini M. Assay-related issues in the measurement of cardiac troponins. Clin Chim Acta 2009; 402: 88-93.
34. Bunk DM, Welch MJ. Characterization of a new certified reference material for human cardiac troponin I. Clin Chem 2006; 52: 212-219
35. Tate JR, Heathcote D, Koerbin G, et al. The harmonization of cardiac troponin I measurement is independent of sample time collection but is dependent on the source of calibrator. Clin Chim Acta 2002; 324: 13-23.
36. Vesper HW, Thienpont LM. Traceability in laboratory medicine. Clin Chem 2009; 55: 1067-1075
37. Thienpont LM, Van Uytfanghe K, De Leenheer AP. Reference measurement systems in clinical chemistry. Clin Chim Acta 2002; 323: 73-87.
38. Panteghini M. Traceability, reference systems and result comparability. Clin Biochem Rev 2007; 28: 97-104.
39. Panteghini M, Bunk DM, Christenson RH, et al. for the IFCC Working Group on Standardization of Troponin I. Standardization of troponin I measurements: An update. Clin Chem Lab Med 2008; 46: 1501-1506
40. Vesper HW, Miller WG, Myers GL. Reference materials and commutability. Clin Biochem Rev 2007: 28: 139-147
41. Bunk DM. Reference materials and reference measurement procedures: An overview from a National Metrology Institute. Clin Biochem Rev 2007: 28: 131-137
42. Stenman UH. Immunoassay standardization: Is it possible, who is responsible, who is capable? Clin Chem 2001; 47: 815-820
43. Noble JE, Wang L, Cerasoli E, et al. An international comparability study to determine the sources of uncertainty associated with a fluorescent ELISA. Clin Chem Lab Med 2008; 46: 1033-1045
44. Panteghini M. Application of traceability concepts to analytical quality control may reconcile total error with uncertainty of measurement. Clin Chem Lab Med 2010; 48: 7-10.
45. National Institute of Standards and Technology (NIST). Certificate of Analysis - Standard Reference Material (SRM) 2921 - Human Cardiac Troponin Complex. Gaithersburg, MD: NIST, 2004.